Efficacy
ESPS 2 was a double-blind, prospective study with 6,602 patients, where Aggrenox®/Asasantin® shows
- significant 23% reduction for the endpoint stroke compared to ASA,
- protective effect against TIA,
- proven additive effect of ER-DP + ASA,
- equally efficacy in women and men.
References
Antiplatelet Trialists' Collaboration. BMJ 1994; 308: 81-106.
PubMed Abstract
Albers et al. Chest 1998; 114: 683S-698S.
PubMed Abstract
Boehringer Ingelheim Data on File 2002.
